Evidence map›Paper›PMID 39416281›Full record

ArticleFrontiers in bioengineering and biotechnology2024

Establishment of a platform based on dual RPA combined with CRISPR/Cas12a for the detection of

Meiying Tan, Xueli Yi, Chuan Liao, Zihan Zhou, Baoyan Ren, Lina Liang, Xuebin Li, Guijiang Wei

Abstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. [Research Progress on the Application of CRISPR/Cas System in Rapid Testing of Drug-Resistant Bacteria in Clinical Practice].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026
    Review
  2. Advances in CRISPR-Cas for Diagnosis and Treatment ofPathogens (Basel, Switzerland) · 2026
    Review
  3. Review
  4. Article
  5. CRISPR/Cas diagnostics forFrontiers in bioengineering and biotechnology · 2026
    Review
  6. Advances in the detection of Drug-Resistant bacteria: current trends and innovations.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Review
  7. Article
  8. Frontiers in cellular and infection microbiology · 2025
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Meiying TanCenter for Medical Laboratory Science, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.
Xueli YiCenter for Medical Laboratory Science, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.
Chuan LiaoCenter for Medical Laboratory Science, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.
Zihan ZhouCenter for Medical Laboratory Science, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.
Baoyan RenModern Industrial College of Biomedicine and Great Health, Youjiang Medical University for Nationalities, Baise, China.
Lina LiangCenter for Medical Laboratory Science, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.
Xuebin LiModern Industrial College of Biomedicine and Great Health, Youjiang Medical University for Nationalities, Baise, China.
Guijiang WeiCenter for Medical Laboratory Science, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carbapenem resistant

Indexed as

carbapenem resistant Klebsiella pneumoniaeCRISPR/Cas12alimit of detectionrecombinase polymerase amplificationsensitivity

Identifiers

PMID39416281
PMCPMC11480703

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.